LOS ANGELES, May 14, 2018 /PRNewswire/ --
GT Biopharma Inc. (OTCQB:
GTBP)(Euronext Paris GTBP.PA) today announced the promotion of Dr.
Raymond W Urbanski MD, PhD to the position of President and Chief
Medical Officer effective immediately. Dr. Urbanski will report to
Shawn Cross, the Company's Chief
Executive Officer.
"I am pleased to announce the promotion of Dr. Urbanski to
President and Chief Medical Officer. The combination of Ray's
experience as a practicing physician and subsequently experience in
industry, where he has served in key leadership positions including
serving as the Chief Medical Officer of one of Pfizer's business
units and as the Chief Medical Officer of Mylan. His training,
depth of knowledge and experience as well as his organizational
acumen has been invaluable as we prepare GT Biopharma for our next
stage of growth," said Shawn M.
Cross, Chairman and Chief Executive Officer of GT Biopharma.
"In addition to pushing forward our pre-clinical and clinical
product candidates, Ray has played a critical role in advancing
other company initiatives including recruiting experienced members
to our scientific advisory board and board of directors,
implementing internal processes and procedures, which are less
visible but very important, as progress towards certain goals
including a NASDAQ up-listing, among others. In short, I am
delighted to have Ray as a senior member of our leadership
team."
Since joining the company in October
2017 Dr. Urbanski has been instrumental in driving key
milestones and initiatives including the transitioning the first
TriKE IND from the University of
Minnesota to GT Biopharma while engaging the FDA in
preparation for human clinical testing to begin in 2H 2018;
implementing processes to expedite the identification and
development of future tumor antigen targets; driving forward our
Bi-specific Antibody Drug Conjugate platform which included the
formation of our Antibody-Drug Conjugate Clinical Advisory Board.
Dr. Urbanski has also been a major factor in developing a strong
working relationship with the University of
Minnesota, Masonic Cancer Center, the epicenter of
innovation for the TriKE and TetraKE platforms.
Dr. Urbanski also represents the company at key international
meetings such as ASH and the upcoming ASCO conferences, attending
investor conferences and recruiting top tier Scientific Advisory
Board members and consultants.
About GT Biopharma, Inc.
GT Biopharma, Inc. is an immuno-oncology biotechnology company
focused on innovative treatments based on the company's proprietary
Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs™ and
TetraKEs) and bispecific antibody-drug conjugate (ADC) platforms.
GT's lead oncology drug candidate, OXS-1550 (DT2219) is a novel
bispecific scFv recombinant fusion protein-drug conjugate composed
of the variable regions of the heavy and light chains of anti-CD19
and anti-CD22 antibodies and a modified form of diphtheria toxin as
its cytotoxic drug payload. OXS-1550 has demonstrated success in
early human clinical trials in patients with relapsed/refractory
B-cell lymphoma or leukemia. In addition, GT's TriKE platform will
address a number of cancer types. GT's nervous system platform is
focused on acquiring or discovering and patenting late-stage,
de-risked, and close-to-market improved treatments for nervous
system diseases (Neurology and Pain) and shepherding them through
the approval process to the NDA. GT Biopharma's neurology products
currently include PainBrake, as well as treatments for the symptoms
of myasthenia gravis, and motion sickness.
Except for historical information contained herein, the
statements in this release are forward-looking and made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are inherently
unreliable and actual results may differ materially. Examples of
forward-looking statements in this news release include statements
regarding the effectiveness of the Company's products, the
potential outcome of clinical studies, the future success of
development activities, the future growth and operating and
financial performance of the Company and the possibility of the
Company uplisting to NASDAQ. Factors which could cause actual
results to differ materially from these forward-looking statements
include such factors as the Company's ability to accomplish its
business initiatives, obtain regulatory approval and protect its
intellectual property; significant fluctuations in marketing
expenses and ability to achieve or grow revenue, or recognize net
income, from the sale of its products and services, as well as the
introduction of competing products, or management's ability to
attract and maintain qualified personnel necessary for the
development and commercialization of its planned products; the
Company's ability to meet the applicable NASDAQ uplisting
requirements, and other information that may be detailed from time
to time in the Company's filings with the United States Securities
and Exchange Commission. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or
otherwise.
Contact:
Westwicke Partners
John Woolford
+(443) 213-0506
john.woolford@westwicke.com
SOURCE GT Biopharma Inc.